BTOG relies solely on income from exhibition/sponsorship at education events and annual conference registration fees to allow it to support and educate thoracic oncology health care professionals and to undertake key activities under our three strategic arms – education, research and representation. Sponsorship does not constitute endorsement, recommendation, or favouring by BTOG.

Diamond Sponsor for 2022

For more than a century, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Today, MSD continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world. For more information about our products and to register with MSD Connect, visit (this link will direct you to an MSD promotional website). For more information about MSD, visit and connect with us @MSDintheUK on Twitter, Instagram, LinkedIn, YouTube and Facebook.

Platinum Sponsors for 2022

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca is based in five different locations across the UK, with its global headquarters in Cambridge. In the UK, around 8,300 employees work in research and development, manufacturing, supply, sales and marketing. We supply 40 different medicines to the NHS. For more information, please visit and follow us on Twitter at @AstraZenecaUK

At Janssen, we envision a world where cancer is a potentially preventable, chronic, or curable disease. To reach this goal, we aim to fundamentally alter the way cancer is understood, diagnosed, and managed. Cancer interception is one of our key strategies for meeting this challenge head on. It means achieving a more robust understanding of the mechanisms involved in the transition of normal cells to a pre-malignant state, offering an opportunity to develop treatments with the potential to stop cancer in its earliest stages. For more information, please visit: Join over 16,000 UK healthcare professionals who have signed up to the information Janssen can offer:

Merck is a science-led organization dedicated to delivering transformative medicines with the goal of making a meaningful difference in the lives of people affected by cancer. Our oncology research efforts aim to leverage our synergistic portfolio in oncogenic pathways, immuno-oncology, and DNA Damage Response (DDR) to tackle challenging tumour types in gastrointestinal, genitourinary, and thoracic cancers. Our curiosity drives our pursuit of treatments for even the most complex cancers, as we work to illuminate a path to scientific breakthroughs that transform patient outcomes. Learn more at

At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. We ensure a tight connection from research to development to commercialisation to rapidly meet the needs of the cancer community, optimising our ability to bring transformative medicines to patients. Our demonstrated leadership in the treatment of haematologic cancers and solid tumours combined with cutting-edge science through multiple platforms, partnerships and therapeutic approaches enable us to bring novel medicines to patients worldwide.

Gold Sponsors for 2022

For Amgen, the key to serving patients is by being the best possible partner to the NHS and the professionals that fuel it. Over the last 40 years, Amgen has developed innovative medicines in cancer and long-term conditions and is immensely proud of the difference made to the lives of people in the UK through these and the services we deliver alongside them, enabling even more value for the system and patients. Committed to driving sustainable solutions that can adapt to an ever-evolving health system, Amgen is proud to serve its people, customers, and patients every day.

Bayer plc aims to develop products that improve people’s quality of life. We concentrate on the research and development of innovative drugs and novel therapeutic approaches to prioritise targets and pathways with the potential to impact not just the treatment of common cancers, but rarer cancers as well. UK healthcare professionals and other relevant UK decision makers can register here to subscribe to electronic communications about Bayer's products, services and events:   Visit for more information.

Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. At Lilly, we are dedicated to developing and delivering innovative medicines that will make a meaningful difference to cancer patients. For us, this means putting an intense focus on the latest scientific advances and collaborating with doctors, other researchers, advocates and payers to ensure our medicines bring value to people living with cancer. People living with cancer are at the centre of what we do. We believe health care makes a difference when striving to improve peoples’ lives. Whether it's treating rare tumour types, leveraging precision medicine, continuing the study of immuno-oncology or discovering new ways to advance existing treatments, we're dedicated to making even greater differences in the lives of people living.

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we strive to use innovative science and digital technologies to create treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. In the UK, we employ approximately 1,500 people to serve healthcare needs across the whole of the UK, as well as supporting the global operations of Novartis. Since 2014, Novartis has invested over £200 million in R&D and is a leading sponsor of clinical trials in the UK. For more information, please visit Novartis UK is on Twitter. Sign up to follow @NovartisUK at

At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 23 approved innovative cancer medicines and biosimilars across more than 30 indications globally, including breast, genitourinary, colorectal, blood and lung cancers, as well as melanoma.    (PP-XLK-GBR-1264 - March 2022)

Roche is a pioneer in pharmaceuticals and diagnostics, focused on advancing science to improve people’s lives. We have created truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. In the UK we employ over 2,000 people who work hard every day to bring our medicines and diagnostics to people who urgently need them. We work from bench to bedside - researching new medicines and diagnostics, running global clinical trials, and collaborating with the NHS to try to ensure rapid uptake and delivery of our products and services. For more information:

Silver Sponsors for 2022

At Boehringer Ingelheim we are taking cancer on. We are collaborating with the oncology community to deliver scientific breakthroughs to transform the lives of patients. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer. Our commitment to innovation has resulted in pioneering treatments for lung cancer and we are advancing a unique pipeline of cancer cell directed agents, immuno-oncology therapies and intelligent combination approaches to help combat many cancers.

Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. We are focused on helping patients in disease areas including oncology, cardiovascular, immunoscience and fibrosis. Each day, our employees work together for patients.

Chugai Pharma UK Ltd is a research-based pharmaceutical company, part of the Roche group. Our mission is to provide innovative medical products and services, for the benefit of the UK medical community and the patients in its care.   Chugai is a Japanese global company, with a rich history and strong position in a number of therapeutic areas including: oncology, haematology and rheumatology, and a growing research pipeline including novel targeted therapies and supportive care agents. Chugai’s European Business Development Team also actively seeks new partners to in-licence and commercialise products through our experienced cross functional team.  Chugai is committed to the highest ethical and moral standards in order to fulfil its corporate social responsibility to society.

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics. The Guardant360 liquid biopsy comprehensive genomic profiling test is the leading, analytically, and clinically validated liquid biopsy assay that effectively detects the four main classes of genomic alterations in 74 well-documented cancer genes, thereby enabling clinicians to identify candidates for targeted therapies and to avoid treatments which are less likely to be effective. It is indicated for all advanced solid tumours, both in first line and at progression. Guardant360 includes most guideline recommended genomic biomarkers, in line with those included on the National Genomic Test Directory, and has a very fast turnaround time, with an average of 7 days from sample receipt in the laboratory to issuing of the report. The test is performed in a single CLIA certified and CAP and ISO15189 accredited central laboratory in Redwood City, California. Since being introduced, Guardant360 has become widely adopted in clinical practice and there are now more than 260 peer-reviewed publications, over 60 of which describe the outcomes achieved when patients are treated in line with their molecular tumour profile identified through Guardant360. The test has been used by over 11,000 oncologists, with more than 250,000 tests performed to date.


Irwin Mitchell has been at the forefront of recovering compensation to improve quality of life and provide for the holistic needs of our clients with asbestos diseases for many decades. Our dedicated and compassionate, specialist lawyers, are leaders in their field, have won many landmark cases, including one of the first to fund the costs of private medical treatments, winning many Appeal Court cases over the decades and fighting for positive changes in the law. We support our clients and their healthcare professionals to optimise the quality of life of our clients and their families. To find out how we can help you or your patients, speak with one of our specialist lawyers. We cover the whole of the UK - you can call us on 0808 149 8004 or contact us online

Leigh Day has specialised in asbestos cases for over 25 years, both in the UK and across the globe. Our Lawyers have represented thousands of clients. We advise our clients on a ‘no win, no fee’ basis and they keep 100% of their compensation. We visit our clients at their home or wherever they may be. We have built up good relationships with Medical Practitioners and Court Experts and we are well known and respected within this area of law. Leigh Day lawyers not only represent clients who have developed an illness but they also have shaped the law through landmark rulings in the Supreme Court which have set precedents which other law firms follow.In addition we were instructed by the leading  asbestos expert Dr. Robin Rudd who brought a claim against John Bridle, an asbestos lobbyist who claims chrysotile products are safe. A higher number of Leigh Day lawyers are ranked in Band 1 than any other law firm, in the independent legal directory Chambers & Partners. One of our lawyers has raised over £60,000 for research to find a cure for mesothelioma, as her father died from mesothelioma. Click to download our Guide for Patients:

Bronze Sponsors for 2022

Fieldfisher is one of the UK's foremost mesothelioma claims practices. We are renowned for our success and commitment in the pursuit of asbestos and mesothelioma claims. Our team act on a 'no win, no fee' basis. Our specialist solicitors will always visit clients at home, regardless of their location. We are ranked as one of the leading practices in Chambers and Partners 2022, who describe us as a "Market-leading industrial disease practice with an outstanding reputation for undertaking mesothelioma and asbestos disease litigation."

GSK oncology is committed to the discovery and development of new oncology therapies that leverage patient-driven science to improve outcomes for patients. GSK’s pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilising modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination. For further information, please visit

Sponsor - Mesothelioma Webinar April 2022

Our national asbestos team, led by Isobel Lovett and based in London and North West England, has a combined experience of over 80 years working for victims of mesothelioma and other asbestos diseases. Our team are hugely proud of their record in achieving successful settlements for our clients.

Founded in 1977, Hodge Jones & Allen remains fully dedicated to helping people defend their rights and resolve personal legal matters to get the very best for every client. We ‘fight for what’s right’

Ranked by Chambers UK legal directory 2022, Described as “impressive and creative lawyers who take on difficult cases.”


Societies at the Virtual BTOG 2022

BTOG extends invitations to various societies to exhibit at its annual conference – societies have not been charged to exhibit at BTOG 2022.

ALK Positive Lung Cancer (UK) is a registered charity established by patients and carers. We support, empower and advocate to improve the overall survival and quality of life of ALK-Positive lung cancer patients in the UK.


  • Have a Facebook group for ALK-positive patients and family which offers mutual support
  • Identify and locate ALK-positive patients through engagement with key healthcare professionals
  • Hold national meetings where ALK-positive patients can hear from and ask questions of experts
  • We liaise with decision makers e.g. NICE, DVLA, NHS and the medical profession to promote the best treatment for patients

Find out more at

EGFR Positive UK is a patient-driven charity committed to providing information and support for EGFR-mutated lung cancer patients and their families. We work to raise awareness of EGFR positive lung cancer and end the stigma associated with lung cancer in general. We support research and advocacy to change EGFR positive lung cancer into a chronic disease that can be managed long-term. Find us on Facebook and join a growing community of fellow EGFR positive patients and their families who are sharing their stories and experiences of living with EGFR positive lung cancer.

Lung Cancer Nursing UK (LCNUK) is a Charitable Incorporated Organisation (CIO) which aims to advance health by providing support, professional development, peer networking and research opportunities for cancer nurse specialists involved in caring for people with lung cancer and mesothelioma.  Membership is open to any specialist nurse who spends more than 50% of their working week or clinical activities in caring for patients with lung cancer and or mesothelioma. or email

Mesothelioma UK is a national specialist resource centre, specifically for the asbestos-related cancer, mesothelioma. The charity provides specialist mesothelioma information, support and education, and to improving the care and treatment for all UK mesothelioma patients and their carers. The charity integrates into NHS front line services through a growing network of specialist mesothelioma nurses, regionally based in NHS hospitals but funded by Mesothelioma UK. In addition to the support provided by our nurses, our vision is to fund new and existing audit and research collaborations with academics, healthcare professionals and the charitable sector. We are 100% reliant on fundraised income and the support of our legal and corporate partners.

Roy Castle Lung Cancer Foundation: We fund research into early detection and patient experience of lung cancer. We are working with Targeted Lung Health Check Programmes to raise awareness of the programme, to overcome potential hurdles and encourage those eligible to attend. It is our aim to ensure that everyone who is invited takes up this vital service. Lung Cancer Connect provides telephone and video support sessions, via a trained facilitator, on various topics including managing symptoms and living with lung cancer. We continue to provide our Keep in Touch service which proved to be invaluable to patients and carers who were more isolated than usual due to the pandemic.

SCTS are an inclusive professional society for all healthcare professionals involved and interested in cardiothoracic surgery. SCTS continues to be an innovative, forward thinking organisation, addressing the interests of patients and the cardiothoracic team including surgeons, trainees and the nursing and allied health professionals. SCTS host one of the largest cardiothoracic surgery conferences in the UK. The SCTS Annual Meeting 2022 will take place as a physical conference on 8th - 10th May 2022 at the ICC Belfast. 3 days of cardiac & thoracic surgery educational sessions by international and national leading experts.

The UK Lung Cancer Coalition (UKLCC) is the UK’s largest multi-interest group in lung cancer. It was set up in 2005 with the founding ambition of tackling poor UK lung cancer survival and, specifically, to double five-year survival by 2015, which was effectively achieved. Despite the devastating impact of COVID-19, it is still focused on its latest survival challenge, of driving up five-year survival cancer to 25 percent by 2025. The UKLCC’s membership includes leading lung cancer experts, senior NHS professionals, charities, and healthcare companies with an interest in fighting lung cancer. For more information about our work and members, visit:

VJOncology is an independent, open-access video journal that provides trusted and up-to-date information for healthcare professionals through innovative digital media – including video interviews, panel discussions, podcasts, editorial features and e-learning courses. We rapidly disseminate the latest news from global medical congresses to keep the oncology community informed.

The Lung Cancer Channel on VJOncology provides the latest updates in lung cancer diagnosis and treatment, and is steered by Professor Sanjay Popat, Professor Martin Reck, Professor Ross Camidge and Dr Melissa Johnson.

With the absence of in-person meetings these past two years, the lung cancer community has desperately missed the opportunities for its experts to get together and discuss advances in the field. VJOncology has introduced The Lung Cancer Sessions – a series of virtual panel discussions featuring leading experts who discuss and debate the key issues of interest in lung cancer. To receive more information about our post-BTOG Lung Cancer Session, sign up to our newsletter here:

VJOncology is pleased to be a media partner for the 20th BTOG Annual Conference – continuing our partnership which started in 2017. Together with BTOG, we aim to keep the lung cancer community abreast of the latest research, its relevance for treating patients in the UK, and the importance of the MDT in thoracic oncology.

View all our interviews with speakers from the 20th BTOG Annual Conference here: